Dual PI3Kδ/CK1ε Inhibition on CLL T Cells
Predictors of Outcome in Patients with CLL and COVID-19
Can Prognosis Assessments Accurately Predict Time to First Treatment in Early-Stage CLL?
CLL and COVID-19: When May Humoral Immunity Therapy Be Indicated?
Subcutaneous Versus Intravenous Rituximab in CLL: Canadian Experience
IGHV Mutations and the Relationship Between Translocation and Time to Treatment in CLL
Biomarker May Aid in the Stratification of Prognostic Groups for CLL
Does UGT2B17 Alter Treatment Response in CLL?
Core Strategies in CLL to Mitigate Risks & Optimize Patient-Centered Care
CAR-T Cell Therapy for Blood Cancer Patients
Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma
Clinical Advances: Individualizing Treatment for Chronic Lymphocytic Leukemia
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Wisconsin Carbone Cancer Center
Helen Diller Family Comprehensive Cancer Center
Siteman Cancer Center
Leukemia & Lymphoma Society
NCCN Guidelines for Patients®